A case report of Hepatoid Carcinoma of the Ovary with peritoneal metastases treated with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy without systemic adjuvant therapy

Samer A. Naffouje (MD)\textsuperscript{a,}\textsuperscript{*}, Richard R. Anderson (MD)\textsuperscript{b}, George I. Salti (MD, FACS)\textsuperscript{c,\textsuperscript{d}}

\textsuperscript{a} Department of General Surgery, University of Illinois Hospital and Health System, Chicago, IL, United States
\textsuperscript{b} Department of Pathology Edward Cancer Center, Naperville, IL, United States
\textsuperscript{c} Department of Surgical Oncology, Edward Cancer Center, Naperville, IL, United States
\textsuperscript{d} Division of Surgical Oncology, University of Illinois at Chicago Medical Center, Chicago, IL, United States

\textbf{A B S T R A C T}

\textbf{BACKGROUND:} Hepatoid Carcinoma of the Ovary (HCO) is a rare subtype of ovarian cancers where malignant cells undergo hepatoid metamorphic changes and cytologically resemble hepatocytes. There are many case reports of HCO in the literature, and patients with these tumors are almost uniformly treated with palliative debulking and conventional adjuvant chemotherapy. To our knowledge, there is only one case report of HCO complicated by peritoneal dissemination that was treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CRS plus HIPEC), followed by adjuvant chemotherapy. 

\textbf{CASE SUMMARY:} A 47-year-old female presented with vague lower abdominal pain. Work-up included imaging studies and biopsies for histopathology which confirmed the diagnosis of hepatoid ovarian carcinoma with synchronous liver metastasis and peritoneal dissemination, without evidence of extraperitoneal disease. She underwent a cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CRS plus HIPEC) with curative intent. Complete cytoreduction was achieved (CC-0). Postoperatively, the patient elected to forgo adjuvant therapy. She continues to be closely followed through clinical and radiological surveillance. On her most recent follow-up visit, she achieved 22 months of disease-free survival.

\textbf{CONCLUSION:} CRS plus HIPEC can be considered as a promising curative approach for HCO with peritoneal dissemination in absence of extraperitoneal disease. Further studies are warranted to determine the role of adjuvant chemotherapy in this relatively rare entity.

\textcopyright 2016 The Author(s). Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. T2-weighed MRI of the pelvis. Pelvic complex mass with bilateral adnexal involvement and omental invasion (asterisk).

Fig. 2. T1-weighed MRI of the abdomen. 4.2 × 4.7 cm liver metastasis in the anterior left lobe (arrow).

Fig. 3. Ovarian parenchymal carcinoma with classic hepatoid morphology (asterisk); uniform, cuboidal cells with eosinophilic cytoplasm.

The pathology report confirmed the presence of hepatoid polygonal malignant cells in the ovarian stroma (Fig. 3) with multiple organ involvement. Malignant cells had strong expression of Hep Par 1, glypican-3, and cytokeratin 7, 8, and 18, whereas cytokeratin 20 was not detected. Negative margins were achieved on the heptectomy specimen, and there was no evidence of cirrhosis in liver.

She underwent serial surveillance imaging every 6 months postoperatively, and achieved 22-months disease-free survival without evidence of intra- or extra-peritoneal recurrence. Her follow up laboratory work showed normalization of AFP and CA-125, and the patient was satisfied with the overall outcome of the procedure. The timeline of the patient’s diagnosis and treatment course is demonstrated in Table 1.

2. Discussion

HCO is a rare malignancy that arises primarily in the ovary, first described in 1987 by Ishikura and Scully [4]. They reported five cases of HCO, two of whom had liver metastases including one who had other abdominal dissemination, similar to our patient. The determination of the tumor’s origin was largely based on clinical manifestation and histopathological features of the specimen, where the lack of squamous, cholangiocellular, or adenofibromatous differentiation would strongly suggest an ovarian origin with hepatoid morphology.

The most prominent microscopic features of HCO are the well demarcated, cuboidal tumor cells arranged in trabeculae or sheets, with eosin staining cytoplasm and hyaline globules on periodic Acid-Schiff. [5]

HCO tumors uniformly stain positive for AFP which is usually found to be elevated in the serum as well [6]. It is critically important to distinguish HCO from hepatoid yolk sac tumors (HYST) and metastatic hepatocellular carcinoma (HCC). The former can be fairly easily ruled out by the absence of Hep-Par 1, a well-characterized positive marker for hepatocellular differentiation, abundant in hepatocytes and hepatoid tumors [7]. On the contrary, discrimination between HCO and metastatic HCC can be extremely challenging, especially in the case of synchronous hepatic and ovarian involvement. The tumor’s origin can be judged according to clinical and pathological facts as mentioned above. Moreover, inhibin positivity has been proposed as a marker to discern HCC-derived cells [8].

Extrahepatic tumors with hepatoid morphology most commonly arise in the stomach [9,10], and less commonly in other viscera. HCO is considered a rare entity with 33 cases documented since Ishikura and Scully’s report [4,6,8,11–33], described in both pre- and post-menopausal females between 35 and 78 years old. The vast majority of patients are found to have advanced disease (stage III/IV) at the time of diagnosis. HCO is particularly known to be locally and regionally aggressive. Metastatic disease most commonly manifests as peritoneal seeding and intraabdominal visceral metastasis and less frequently as distant hematogenous spread. In addition to the current report, one case was managed surgically with CRS plus HIPEC using paclitaxel as an intraoperative agent [26]. The patient achieved a complete cytreduction (CC = 0), and was further treated with adjuvant chemotherapy consisting of paclitaxel and carboplatin. The documented disease-free survival was 28 months. In another case report sorafenib was used due to paclitaxel intolerance, however was unsuccessful in halting the disease progression [8].

Interestingly, our patient experienced a significant recurrence-free survival of 21 months documented by radiologic and laboratory testing following the use of a different HIPEC agent and waiver of adjuvant therapy. This observation raises the query of whether such a long-term outcome in HCO is more contingent on complete cytreduction rather than adjuvant regimens in the absence of extra-peritoneal disease. This would be in contrast to other ovarian carcinomas with peritoneal dissemination, such as germ cell tumors, whose mainstay of treatment is the adjuvant or neoadjuvant chemotherapy regardless of the completeness of debulking and irrespective of the size of residual disease [34].
Table 1
The timeline of diagnosis, treatment, and follow up of our patient.

| Date          | Event Description                                                                 |
|---------------|------------------------------------------------------------------------------------|
| August 22nd, 2014 | Initial presentation with vague lower abdominal pain                              |
| August 29th, 2014 | Abdominal ultrasound revealed a liver lesion and lower abdominal mass              |
| September 5th, 2014 | Abdominal CT revealed an ill-defined left hepatic lobe mass with multiple enhancing soft tissue masses in lower abdomen and pelvis coalescing at 10 cm |
| September 7th, 2014 | Abdominal MRI confirmed the above findings and detected peritoneal carcinomatosis |
| September 12th, 2014 | CT-guided biopsy of the pelvis mass was positive for malignancy and consistent with HCC/HCO |
| September 13th, 2014 | Laboratory work showed elevated AFP and CA-125                                   |
| October 16th, 2014 | Patient consulted for CRS plus HIPEC                                              |
| October 15th, 2014 | Abdominal MRI was repeated: no evidence of disease progression                   |
| October 20th, 2014 | CRS plus HIPEC                                                                     |
| October 22nd, 2014 | Discharge from ICU                                                                 |
| October 27th, 2014 | Pelvic abscess requiring IR drainage                                              |
| November 4th, 2014 | Discharge from hospital                                                            |
| January 14th, 2015 | Abdominal MRI was negative for recurrence. AFP and CA-125 normalized.             |
| April 13th, 2015  | Abdominal MRI was negative for recurrence. Tumor markers were normal.             |
| July 13th, 2015   | Abdominal MRI was negative for recurrence. Tumor markers were normal.             |
| October 19th, 2015 | Abdominal MRI was negative for recurrence. Tumor markers were normal.             |
| April 14th, 2016  | Abdominal MRI was negative for recurrence. Tumor markers were normal.             |
| August 8th, 2016  | Abdominal MRI was negative for recurrence. Tumor markers were normal.             |

In conclusion, HCO remains a rare diagnosis and all evidence available in the literature is based on case reports and series. At this time, there is no consensus regarding the optimal management of HCO, given the lack of high-level evidence. Current management relies on systemic chemotherapy or immunomodulation with various levels of success as reported above. The combination of surgical debulking and systemic therapy has been proposed in one case report. Our current report confirms that CRS plus HIPEC can be applied as a promising, and possible curative, option for this disease. What we propose as a learning point is that adjuvant therapy may be waived safely in this patient population if complete cytoreduction is achieved and in absence of extraperitoneal spread. Further evidence is necessary to confirm these findings.

Conflicts of interest

The authors have no financial disclosures nor conflicts of interest to report.

Funding

No funding sources to report.

Ethical approval

Ethical approval was not required for this case report presentation.

Consent

Informed consent obtained from the patient.

Author contribution

Samer A. Naffouje: Study design, data collection, writing the paper.Richard R. Anderson: Histologic analysis, confirmation of pathology findings.George I. Salti: Surgical procedure (CRS plus HIPEC), follow up plan.

Guarantor

George I. Salti.

Acknowledgements

This work was presented at Eleventh International Regional Cancer Therapies Symposium (Chandler, Arizona, February 2016). Informed Consent and IRB approval were obtained. Patient’s data was de-identified. The authors have no financial disclosures nor conflicts of interest to report.

References

[1] J. Gagnier, G. Kienle, D.G. Altman, D. Moher, H. Sox, D.S. Riley, The CARE Group, The CARE guidelines: consensus-based clinical case report guideline development, J. Clin. Epidemiol. 67 (1) (2016) 46–51.
[2] P.H. Sugarbaker, Cytoreductive surgery using peritonectomy and visceral resections for peritoneal surface malignancy, Transl. Gastrointest. Cancer 2 (2013) 54–74.
[3] D. Morris, Peritonectomy HIPEC—contemporary results, indications, Chin. J. Cancer Res. 25 (4) (2013) 373–374.
[4] H. Ishikura, R.E. Scully, Hepatoid carcinoma of the ovary: a newly described tumor, Cancer 60 (1987) 2775–2784.
[5] J.H. Lefkowitz, Liver look-alike: hepatoid ovarian carcinoma, Hepatology 8 (5) (1988) 1168–1169.
[6] S. Yigit, M.A. Uyaroglu, Z. Kus, N. Ekinci, O. Ortekin, Hepatoid carcinoma of the ovary: immunohistochemical finding of one case and literature review, Int. J. Gynecol. Cancer 16 (3) (2006) 1439–1441.
[7] Z. Fan, M. van de Rijn, K. Montgomery, R.V. Rouse, Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 576 tumors tested using tissue microarrays and conventional tissue sections, Modern Pathol. 16 (February 2) (2003) 137–144.
[8] M. Pandey, C. Trucza, Hepatoid Carcinoma of the ovary, J. Clin. Oncol. 29 (May 15) (2011) e446–e448 (20).
[9] J.S. Su, Y.T. Chen, R.C. Wang, C.Y. Wu, S.W. Lee, T.Y. Lee, Clinicopathological characteristics in the differential diagnosis of hepatoid adenocarcinoma: a literature review, World J. Gastroenterol. 19 (3) (2013) 321–327.
[10] R.H. Young, D.J. Gersell, P.B. Clement, R.E. Scully, Hepatocellular carcinoma metastatic to the ovary: a report of three cases discovered during life with discussion of the differential diagnosis of hepatoid tumors of the ovary, Hum. Pathol. 23 (5) (1992) 574–580.
[11] M. Matsuta, H. Ishikura, K. Murakami, T. Kagabu, I. Nishiya, Hepatoid carcinoma of the ovary: a case report, Int. J. Gynecol. Pathol. 10 (1991) 302–310.
[12] K. Tanakoshi, J. Horio, T. Okamoto, K. Sakakibara, S. Hattori, A case report of hepatoid carcinoma of the ovary, Acta Obstetrics Gynaecol. Jpn. 45 (5) (1993) 479–481.
[13] J. Badreddine, Y. Rabouille, J.F. Heron, A.M. Mandard, Ovarian tumor with hepatoid differentiation. Report of one case and review of the literature, Ann. Pathol. 13 (1993) 37–39.
[14] T. Nishida, T. Sugiyama, A. Kataoka, K. Ushijima, S. Ota, S. Iwanaga, M. Yukushi, Ovarian hepaticoid carcinoma without staining for alpha-fetoprotein in the primary site, Int. J. Gynecol. Cancer 5 (1995) 314–318.
[15] J.P. Scully, R.W. Brown, T. Jobling, Combined ovarian serous papillary and hepatoid carcinoma, Gynecol. Oncol. 63 (1996) 138–142.
[16] E. Maymon, P. Puira, M. Mazor, A. Bashiri, T. Silberstein, I. Yanai-Inbar, Primary hepatoid carcinoma of the ovary in pregnancy, Am. J. Obstetrics Gynecol. 179 (1998) 820–822.
[17] P. Trivedi, K. Dave, M. Shah, N. Karelia, D. Patel, M. Wadhwa, Hepatoid carcinoma of the ovary—a case report, Eur. J. Gynaecol. Oncol. 15(2) (1998) 167–169.
[18] H. Senzaki, Y. Kiyozuka, H. Mizuoka, et al., An autopsy case of Hepatoid carcinoma of the ovary with PIVKA-II production: immunohistochemical study and literature review, Pathol. Int. 49 (2002) 164–169.
[19] C.H. Lee, K.G. Huang, S.H. Ueng, H. Swei, H.Y. Chueh, C.H. Lai, A hepatoid carcinoma of the ovary, Acta Obstet. Gynecol. Scand. 81 (2002) 1080–1082.
[20] Y. Watanabe, M. Unemoto, H. Ueda, H. Nakai, H. Hoshuai, K. Noda, Cytopathologic and clinicopathologic features of ovarian hepatoid carcinoma: a case report, Acta Cytol. 47 (2003) 78–82.
[21] N. Tsuchiya, T. Kishimoto, Y. Supradita, Y. Nagai, T. Nikaido, H. Ishikura, Hepatoid carcinoma of the ovary: a report of three cases admixed with a common surface epithelial carcinoma, Int. J. Gynecol. Pathol. 22 (2003) 266–271.
[22] J. Tsung, P. Yang, Hepatoid carcinoma of the ovary: characteristics of its immunoreactivity: a case report, Eur. J. Gynaecol. Oncol. 25 (6) (2004) 745–748.
[23] J.E. Kwon, S.H. Kim, N.H. Cho, No ancillary finding is valid to distinguish a primary ovarian hepatoid carcinoma from metastatic hepatocellular carcinoma, Int. J. Gynecol. Cancer 16 (2006) 1691–1694.
[24] J. Lazaro, D. Rubio, M. Repolles, et al., Hepatoid carcinoma of the ovary and management, Acta Obstetrica Gynecol. 86 (2007) 498–505.
[25] H. Ozan, H. Nazhoglu, S. Ozuyal, A case of hepatoid carcinoma of the ovary, Eur. J. Gynaecol. Oncol. 5 (2008) 556–557.
[26] E.T. Gonzalez, M. Arguelles, J.A. Jimenez-Hefferman, P. Dhimes, B. Vicandi, F. Pinedo, Cytopathologic features of hepatoid carcinoma of the ovary: a case report with immunocytologic evaluation of HepPar1, Acta Cytol. 52 (2008) 490–494.
[27] A. Zizi-Sermpezoglou, N. Petракopoulou, M.E. Nikolaidou, N. Tepelelis, V. Savvidou, T. Vasilakaki, Hepatoid carcinoma of the ovary: a case report and review of the literature, Eur. J. Gynaecol. Oncol. 30 (2009) 341–343.
[28] J. Sun, G. Tang, G. Dong, Hepatoid carcinoma of the ovary: a case report. 2009; 43(3): 324–325.
[29] A. D’Antonio, G. De Dominicis, M. Addesso, A. Caleo, A. Boscaino, Hepatoid carcinoma of the ovary with sex cord stromal tumor: a previously unrecognized association, Arch. Gynecol. Obstetrics 281 (2010) 765–768.
[30] X. Liu, X. Wang, F. Zhu, Hepatoid carcinoma of the ovary: a case report and review of the literature, Oncol. Lett. 4 (2012) 947–950.
[31] P. Campos, J. Martinez, A. Torroba, F. Machado, P. Paricio, Peritoneal dissemination of hepatoid carcinoma of the ovary treated with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy, Case Rep. Med. (2013).
[32] Wang, et al., Clinical and pathological features of hepatoid carcinoma of the ovary, World J. Surg. Oncol. 11 (2013) 29.
[33] L.K. Randolph, M.K. Hopkins, M.P. Hopkins, D.A. Wasdahl, Hepatoid carcinoma of the ovary: a case report and review of the literature, Gynecol. Oncol. Rep. 18 (June 13) (2015) 64–67.
[34] U.D. Bafna, K. Umadevi, C. Kumaran, D.S. Nagarathna, P. Shashikala, R. Tanseem, Germ cell tumors of the ovary: is there a role for aggressive cytoreductive surgery for nondysgerminomatous tumors? Int. J. Gynecol. Cancer 11 (July–August 4) (2001) 300–304.